Compare ISSC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISSC | DCTH |
|---|---|---|
| Founded | 1988 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.6M | 372.5M |
| IPO Year | 2000 | 2015 |
| Metric | ISSC | DCTH |
|---|---|---|
| Price | $16.34 | $12.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $18.25 | ★ $22.00 |
| AVG Volume (30 Days) | 374.9K | ★ 552.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 107.53 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.95 | $24.54 |
| Revenue Next Year | $6.82 | $33.15 |
| P/E Ratio | $39.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.13 | $8.12 |
| 52 Week High | $30.98 | $13.72 |
| Indicator | ISSC | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 61.50 |
| Support Level | $15.07 | $10.31 |
| Resistance Level | $19.92 | $12.34 |
| Average True Range (ATR) | 1.07 | 0.62 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 11.35 | 91.72 |
Innovative Solutions and Support Inc is a systems integrator that designs, manufactures, sells, and services air data equipment, engine display systems, standby equipment, primary flight guidance, and cockpit display systems for retrofit applications and original equipment manufacturers. The company supplies integrated Flight Management Systems, Flat Panel Display Systems, Integrated Standby Units, Positioning System receivers that enable reduced carbon footprint navigation, and an Autothrottle, which allows a pilot to automatically control the power setting of the engine and is designed to reduce pilot workload and enhance safety. It sells its products to both the OEM and the retrofit markets.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.